There are various errors contained in the references 6, 7, 8, 9, 10, 25, 28, 29, 39, 40 and 43. A summary of issues is as follows:

\* References 6 - 10 contain incorrect information and numbering. They should read as follows:
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\* Reference 25, 28 and 29 should be removed.

\* Reference 39 is incorrect and should read as follows:

Lipinski CA (2004) Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today: Technologies 4: 337-341.

\* Reference 40 is incorrect and should read as follows:

Wager T, Verhoest P, Villalobos A (2010) Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties. ACS Chem Neurosci 1.

\* Reference 43 is incorrect and should read as follows:

Sykes ML, Avery VM (2009) A luciferase based viability assay for ATP detection in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. Parasit Vectors 2: 54.
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